Decreased numbers of platelet alpha-adrenergic binding sites in diabetes mellitus.
Eleven men with diabetes mellitus were compared with 45 male controls for platelet alpha-adrenergic binding sites by using [3H]dihydroergocryptine (DHE) as the radioligand antagonist. There was no difference between the two for binding affinity, but the number of sites was 430 +/- 30 (means +/- SEM) for diabetic subjects and 574 +/- 29 for controls (P = .005). Decreased sites were related to increased glycosylated hemoglobin levels (P = .002). There was no relationship between the decreased sites and catecholamine levels, duration of disease, body weight, or fasting blood sugar. Hence, binding sites were inversely related to control, but further studies are needed to define the pathophysiologic significance of this.
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D001792:Blood Platelets / Q000032:analysis*; D002395:Catecholamines / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood*; D004088:Dihydroergotoxine; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011869:Radioligand Assay; D011942:Receptors, Adrenergic, alpha / Q000032:analysis*
D001786:Blood Glucose; D002395:Catecholamines; D004088:Dihydroergotoxine; D006442:Glycated Hemoglobin; D011942:Receptors, Adrenergic, alpha